Blog
39 Articles

New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.

KRYSTAL-1 Trial Shows Promising Activity in Pancreas and Other GI Cancers
Dr. Tanios Bekaii-Saab reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer.

Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.

New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.

Crafting a Medical Family Tree
Dr. Diane Simeone and genetic counselor Jessica Everett explain why it is important to create a medical family tree for pancreatic cancer.

Improving Access to Genetic Testing and Counseling
Dr. Angela Bradbury is leading a study on access to genetic testing and genetic counseling, including a telehealth option.

The Future of Pancreatic Cancer Treatment
Dr. Anil Rustgi discusses the latest developments in pancreatic cancer treatment and the direction of current research in early detection.

High-Dose Vitamin C Targeting KRAS and BRAF in Pancreatic Cancer
Dr. Manish Shah leads a clinical trial of high-dose vitamin C targeting KRAS and BRAF mutations in solid-tumor cancers, including pancreatic cancer.